Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Nifurtimox (Primary)
- Indications Chagas disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 13 Jul 2018 Planned End Date changed from 15 Nov 2018 to 15 May 2019.
- 13 Jul 2018 Planned primary completion date changed from 12 Oct 2018 to 19 Mar 2019.
- 13 Jul 2018 Planned initiation date changed from 3 Sep 2018 to 10 Nov 2018.